Epileptic Disorders 2011-03-01

Treatment of malignant migrating partial epilepsy of infancy with rufinamide: report of five cases.

Martina Vendrame, Annapurna Poduri, Tobias Loddenkemper, Gerhard Kluger, Giangennaro Coppola, Sanjeev V Kothare

Index: Epileptic Disord. 13(1) , 18-21, (2011)

Full Text: HTML

Abstract

The syndrome of malignant migrating partial seizures of infancy (MMPEI) is characterized by early onset of multiple seizures types, highly pharmaco-resistant seizures, and overall poor prognosis. In this study, we investigated retrospectively the efficacy of rufinamide (RUF) in five infants with MMPEI, by examining seizure type and frequency, EEG features and antiepileptic drug use. The data demonstrate that two of the five patients showed good efficacy and tolerability for RUF with a > 50% reduction in seizure frequency. The use of RUF for the treatment of MMPEI may therefore provide some hope for such infants and should be further validated. [Published with video sequences].

Related Compounds

  • Rufinamide

Related Articles:

Dose-dependent pharmacokinetics and brain penetration of rufinamide following intravenous and oral administration to rats.

2015-02-20

[Eur. J. Pharm. Sci. 68 , 106-13, (2015)]

Toxicological screening of human plasma by on-line SPE-HPLC-DAD: identification and quantification of basic drugs and metabolites.

2015-06-01

[Biomed. Chromatogr. 29 , 935-52, (2015)]

Rufinamide for the treatment of Lennox-Gastaut syndrome.

2011-04-01

[Expert Opin. Pharmacother. 12(5) , 801-6, (2011)]

Bioavailability of three rufinamide oral suspensions compared with the marketed 400-mg tablet formulation: results from a randomized-sequence, open-label, four-period, four-sequence crossover study in healthy subjects.

2011-01-01

[Clin. Ther. 33(1) , 146-57, (2011)]

Rufinamide from clinical trials to clinical practice in the United States and Europe.

2011-05-01

[Epileptic Disord. 13 Suppl 1 , S27-43, (2011)]

More Articles...